Restriction of PD-1 function by cis -PD-L1/CD80 interactions is required for optimal T cell responses
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Sparing T cells from inhibition Programmed cell death 1 (PD-1) is an inhibitory receptor that normally keeps T cell immune responses in check. Immunotherapy targeting PD-1 has proven successful for certain types of cancer, but it remains unclear how PD-1 is regulated. Sugiura et al. found that a costimulatory molecule, CD80, can restrict PD-1 function during the activation of T lymphocytes. Binding of CD80 to the PD-1 ligand PD-L1 in cis on primary activated dendritic cells interfered with the ability of PD-L1 to access PD-1 on T cells, which would otherwise have inhibited T cell activation. Functional insights into PD-L1–CD80 interactions may explain the outcomes of anti–PD-1 and anti–PD-L1 cancer therapy. Science , this issue p. 558
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, PD‐L1 can interact in cis with Cluster of differentiation 80 (CD80) to PD‐1 [276, 277, 278], which may disturb the PD‐L1 and PD‐1 interaction and the CTLA4 and CD80 interaction and also maintain the flexibility of CD80 to trigger the signaling of CD28 [277, 279].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [278]
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Bellmunt, J., Burris, H. A., Petrylak, D. P., Teng, S.-L., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,381
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
Cited by
Items 201–300 of 393
Handelsman, S., Overbey, J., Chen, K. Y., Lee, J., Haj, D., & Li, Y. (2023) · Cells · doi:10.3390/cells12121609 · Cited by 17
Human inherited PD-L1 deficiency is clinically and immunologically less severe than PD-1 deficiency.
Johnson, M. B., Ogishi, M., Domingo‐Vila, C., Franco, E. D., Wakeling, M. N., Imane, Z., Resnick, B., Williams, E., Galão, R. P., Caswell, R. C., et al. (2024) · PubMed Central · doi:10.1084/jem.20231704 · Cited by 27
Cowpox virus encodes a protein that binds B7.1 and B7.2 and subverts T cell costimulation
Wang, X., Piersma, S. J., Elliott, J. I., Errico, J. M., Gainey, M. D., Yang, L., Nelson, C. A., Yokoyama, W. M., & Fremont, D. H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1909414116 · Cited by 15
Tormanen, K., Wang, S., & Ghiasi, H. (2019) · Journal of Virology · doi:10.1128/jvi.01511-19 · Cited by 15
Raza, A., Mohsen, R., Kanbour, A., Gul, A. R. Z., Philip, A., Vijayakumar, S., Hydrose, S., Prabhu, K. S., Al-Suwaidi, A. K., Inchakalody, V. P., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1157100 · Cited by 15
Maccaferri, M., Pisciotta, A., Carnevale, G., Salvarani, C., & Pignatti, E. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1440974 · Cited by 15
Lipid Metabolism and Immune Checkpoints
Liao, Q., Zhou, Y., Xia, L., & Cao, D. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6785-2_12 · Cited by 15
Rossi, E., Zizzari, I. G., Filippo, A. D., Acampora, A., Pagliara, M. M., Sammarco, M. G., Simmaco, M., Lionetto, L., Botticelli, A., Bria, E., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2034377 · Cited by 17
Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
Long, Y., Yu, X., Chen, R., Tong, Y., & Gong, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.910704 · Cited by 16
Tannig, P., Peter, A. S., Lapuente, D., Klessing, S., Damm, D., Tenbusch, M., Überla, K., & Temchura, V. (2020) · Vaccines · doi:10.3390/vaccines8010027 · Cited by 14
Immune checkpoints in rheumatoid arthritis: progress and promise
Small, A., Lowe, K., & Wechalekar, M. D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1285554 · Cited by 14
Mendoza, M. S., Romero‐Garcia, S., Lemini, C., & Prado-García, H. (2021) · Journal of Immunology Research · doi:10.1155/2021/6668573 · Cited by 14
Stifter, K., Dekhtiarenko, I., Krieger, J., Tissot, A. C., Seufferlein, T. T. W., Wagner, M., & Schirmbeck, R. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.04.003 · Cited by 13
Huang, C.-L., Gan, G. N., & Zhang, J. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00898-y · Cited by 14
Huang, S., Zheng, G., & Yang, K. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03212-5 · Cited by 12
Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer
Gorgulho, C. M., Krishnamurthy, A., Lanzi, A., Galon, J., Housseau, F., Kaneno, R., & Lotze, M. T. (2021) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000357 · Cited by 16
Tan, Y., Xu, Q. R., Wu, Z., Zhang, W., Li, B., Zhang, B., Xu, X., Zhang, B., Yan, K., Song, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.783335 · Cited by 14
Diverse roles of dendritic cell and regulatory T cell crosstalk in controlling health and disease
Yamazaki, S. (2024) · International Immunology · doi:10.1093/intimm/dxae042 · Cited by 11
Rigid, bivalent CTLA-4 binding to CD80 is required to disrupt the cis CD80/PD-L1 interaction
Robinson, M. A., Kennedy, A., Orozco, C. T., Chen, H., Waters, E., Giovacchini, D., Yeung, K., Filer, L., Hinze, C., Lloyd, C., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114768 · Cited by 13
Contributions of PD‐L1 reverse signaling to dendritic cell trafficking
Tamburini, B. A. J. (2021) · FEBS Journal · doi:10.1111/febs.16084 · Cited by 12
Li, Y., Wang, H., Pan, Y., Wang, S., Zhang, Z., Zhou, H., Xu, M., & Liu, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1125299 · Cited by 12
Zheng, Y., Liu, X., Li, N., Zhao, A., Sun, Z., Wang, M., & Luo, J. (2023) · Radiation Oncology Journal · doi:10.3857/roj.2023.00185 · Cited by 11
Huang, Y., Yoon, C. H., Gandhi, A. K., Hanley, T., Castrillon, C. E., Kondo, Y., Lin, X., Kim, W., Yang, C., Driouchi, A., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00525-8 · Cited by 11
Corvigno, S., Mezheyeuski, A., de la Fuente, L. M., Westbom-Fremer, S., Carlson, J. W., Fernebro, J., Åvall-Lundqvist, E. H., Kannisto, P., Hedenfalk, I. A., Malander, S., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.09.041 · Cited by 11
Development of anti-feline PD-1 antibody and its functional analysis
Nishibori, S., Kaneko, M. K., Nakagawa, T., Nishigaki, K., Kato, Y., Igase, M., & Mizuno, T. (2023) · Scientific Reports · doi:10.1038/s41598-023-31543-6 · Cited by 10
Immune activation of the p75 neurotrophin receptor: implications in neuroinflammation
Danelon, V., Garrett-Thomson, S. C., Almo, S. C., Lee, F. S., & Hempstead, B. L. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1305574 · Cited by 12
Pediatric nephrotic syndrome: The interplay of oxidative stress and inflammation
Simachew, Y. M., Mihajlović, M., Antonić, T., Miloševski‐Lomić, G., Peco‐Antić, A., Jovanović, D. J., Paripović, D., & Stefanović, A. (2023) · Journal of Medical Biochemistry · doi:10.5937/jomb0-46526 · Cited by 12
Single-cell analysis of diquat-induced oxidative stress and its impact on organ-specific toxicity
Chen, Z., Lin, G., Ye, K., Wang, J., Tang, M., Lai, K., Yuan, Y., Lin, S., Dai, X., Chen, H., et al. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.118246 · Cited by 14
Kwok, T., Silva, I., Korpe, S., Dong, H., & Lancaster, J. N. (2025) · iScience · doi:10.1016/j.isci.2025.113538 · Cited by 12
PD-1, BTLA and TIGIT as therapeutic targets for rheumatic disease
Kuchroo, J. R., Goldman, N., & Sharpe, A. H. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01296-9 · Cited by 10
Adaptive resistance in cancer immunotherapy
Yang, K. E., Yang, C., Xiong, K., Hao, J., & Ye, L. (2026) · Cellular and Molecular Immunology · doi:10.1038/s41423-026-01424-9 · Cited by 12
CD80-Fc fusion protein as a potential cancer immunotherapy strategy
Wang, S., Hu, P., Fan, J., Zou, J., Hong, W., Huang, X., Pan, D., Chen, H., Zhu, Y. Z., & Ye, L. (2023) · Antibody Therapeutics · doi:10.1093/abt/tbad029 · Cited by 11
Ye, H., Yan, J., Ge, C., Wu, F., Zhu, J., Yin, M., Xie, L., Zhou, Z., & Yin, L. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.149093 · Cited by 10
Zuber, J., Léon, J., Déchanet‐Merville, J., & Kaminski, H. (2024) · American Journal of Transplantation · doi:10.1016/j.ajt.2024.09.035 · Cited by 12
Dimers Aren’t Forever: CD80 Breaks up with PD-L1
Sansom, D. M., & Walker, L. S. K. (2019) · Immunity · doi:10.1016/j.immuni.2019.11.011 · Cited by 12
Epigenetic mechanisms of liver tumor resistance to immunotherapy
Sanceau, J., & Gougèlet, A. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i9.979 · Cited by 10
Dimerization of Transmembrane Proteins in Cancer Immunotherapy
Li, L., & Li, J. (2023) · Membranes · doi:10.3390/membranes13040393 · Cited by 12
Recent Advances in Immune Regulation by Targeting Dendritic Cells using Small Interfering RNAs
Shahverdi, M., Alamdari-Palangi, V., Alipour, S., Jolfayi, A. G., Masoumi, J., Maleki, L. A., Rostamlou, A., & Baradaran, B. (2024) · Current Molecular Medicine · doi:10.2174/0115665240303370240530120450 · Cited by 10
Zheng, R., Ni, Y., Li, Q., Chen, Z., Huang, C., Zhao, L., Chen, X., & Li, S. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.08.013 · Cited by 10
Lu, X., Sang, D., Zhang, Y., & Yuan, Q. (2022) · Clinics · doi:10.1016/j.clinsp.2022.100123 · Cited by 9
Cao, C., Xu, M., Peng, T., Liu, X., Lin, S., Xu, Y., Chu, T., Liu, S., Wu, P., Hu, B., et al. (2025) · Genome Medicine · doi:10.1186/s13073-025-01515-8 · Cited by 12
Wang, J., Zhang, Y., Chen, Q., Wang, X., Cui, R., & Hou, P. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102559 · Cited by 8
Urban, V. A., Nazarenko, P. N. P., Перепечко, С. А., & Veresov, V. G. (2022) · Molecular Simulation · doi:10.1080/08927022.2022.2080824 · Cited by 8
Davar, D., Cavalcante, L. L., Lakhani, N. J., Moser, J. C., Millward, M., McKean, M. A., Voskoboynik, M., Sanborn, R. E., Grewal, J. S., Narayan, A., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009474 · Cited by 9
Zhao, Q., Su, X., Xue, J., Liu, Y., Zhu, J., Cai, X., & Qin, S. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03769-4 · Cited by 9
Context-restricted PD-(L)1 checkpoint agonism by CTLA4-Ig therapies inhibits T cell activity
Oxley, E. P., Kershaw, N. J., Louis, C., Goodall, K. J., Garwood, M. M., Ho, S. M. J., Voo, V. T. F., Park, H.-Y., Iaria, J., Wong, L. L. L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114834 · Cited by 11
Wu, J., Sun, Y., Li, J., Ai, M., You, L., Shi, J., & Yu, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.763886 · Cited by 8
Significance of CD80 as a Prognostic and Immunotherapeutic Biomarker in Lung Adenocarcinoma
Feng, W., He, Z., Shi, L., Zhu, Z., & Ma, H. (2023) · Biochemical Genetics · doi:10.1007/s10528-023-10343-7 · Cited by 10
Mazerolles, F. (2024) · Human Immunology · doi:10.1016/j.humimm.2024.110831 · Cited by 8
Human immunomodulatory ligand B7-1 mediates synaptic remodeling via the p75 neurotrophin receptor
Morano, N. C., Smith, R. S., Danelon, V., Schreiner, R. P., Patel, U., Herrera, N. G., Smith, C., Olson, S. M., Lærke, M. K., Celikgil, A., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157002 · Cited by 8
Catch and release: freeing up PD-L1 ameliorates autoimmunity
Grebinoski, S., Gocher, A. M., & Vignali, D. A. A. (2022) · Nature Immunology · doi:10.1038/s41590-022-01140-2 · Cited by 8
Zhao, Y., Zhang, D., Meng, L., Shan, S., Zhang, C., Deng, Z., Han, C., & Kong, L. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.030 · Cited by 7
Regulation of immune checkpoint molecules in cancer immune evasion and therapy
Eris, C., Zu, C., Xiao, Y., Platten, M., & Sun, C. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00934-y · Cited by 11
Shao, Y., Yang, W. Y., Nanayakkara, G., Saaoud, F., Issa, M. B., Xu, K., Lu, Y., Jiang, X., Mohsin, S., Wang, H., et al. (2024) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2024.100022 · Cited by 12
Bosma, D. M. T., Busselaar, J., Staal, M. D., Frijlink, E., Mack, M., Salerno, F., & Borst, J. G. (2025) · Immunology Letters · doi:10.1016/j.imlet.2025.107022 · Cited by 7
Miura, Y., Isogai, S., Maeda, S., & Kanazawa, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-20694-7 · Cited by 9
Ebrahimi, S., Habibzadeh, A., Khojasteh‐Kaffash, S., Valizadeh, P., Samieefar, N., & Rezaei, N. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104225 · Cited by 7
Toffoli, E. C., van Vliet, A. A., Forbes, C., Arns, A. J., Verheul, H. M. W., Tuynman, J. B., van der Vliet, H. J., Spanholtz, J., & de Gruijl, T. D. (2024) · Clinical & Experimental Immunology · doi:10.1093/cei/uxae007 · Cited by 7
Zhao, Y., Xiao, Y., Hu, Z., Wang, J., Xu, Z., Mo, Y., Guojun, Q., Chen, K., Wu, W., & Ma, W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1067305 · Cited by 9
Gramantieri, L., Montagner, A., Arleo, A., Suzzi, F., Bassi, C., Tovoli, F., Bruccoleri, M., Alimenti, E., Fornari, F., Iavarone, M. A., et al. (2025) · ESMO Open · doi:10.1016/j.esmoop.2025.104289 · Cited by 6
Jung, H., Devant, P., Ching, C., Ota, M., Dann, E., Zhu, R., Modak, C., Vasquez-Ibarra, A., Hamilton, J. R., Steinhart, Z., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03258-2 · Cited by 8
Fang, L., Feng, R., Liang, W., Liu, F., Bian, G., Yu, C., Guo, H., Cao, Y., Liu, M., Zuo, J., et al. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17305 · Cited by 7
Duhen, T. M., Gough, M. J., Leidner, R. S., & Stanton, S. E. (2022) · Frontiers in Oral Health · doi:10.3389/froh.2022.902160 · Cited by 6
Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma
Saito, R., Sawada, Y., & Nakamura, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041957 · Cited by 6
Dai, Y., Muaibati, M., Xie, W., Abasi, A., Li, K., Tong, Q., Zhang, T., Meng, Y., Zhuang, L., & Huang, X. (2021) · Cancer Investigation · doi:10.1080/07357907.2021.2012188 · Cited by 6
Ding, Y., Chen, C., Ma, S., Sheng, X., Zhao, F., Peng, J., Dong, H., Ma, C., & Li, C. (2022) · 癌症:英文版 · doi:10.1002/cac2.12337 · Cited by 6
Xu, W., Xu, J., Li, P., Xu, D., Cheng, H., Zheng, H., Zhang, L., Liu, M., Ye, S., Jiang, M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1479399 · Cited by 6
Strikwerda, M., Weerstand, S. A., Burchell, G. L., Tromp, J. M., Mom, C. H., & de Gruijl, T. D. (2025) · Tumour Virus Research · doi:10.1016/j.tvr.2025.200323 · Cited by 6
Duffy, F. J., Neal, M. L., Plumlee, C. R., Cohen, S. B., Gern, B. H., Diercks, A. H., Gerner, M. Y., Urdahl, K. B., & Aitchison, J. D. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1013635 · Cited by 7
Wang, S., Hu, P., Zhang, X., Fan, J., Zou, J., Hong, W., Huang, X., Pan, D., Chen, H., Ju, D., et al. (2025) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-025-13419-z · Cited by 5
Zhang, Z., Li, Y., Chen, N., Li, H., Chen, S., Cui, X., Shao, H., Wei, L., Ma, J., Zhang, S., et al. (2023) · Journal of Neuroinflammation · doi:10.1186/s12974-023-02707-y · Cited by 5
Su, Z., Dhusia, K., & Wu, Y. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008825 · Cited by 5
NPM1 is a Novel Therapeutic Target and Prognostic Biomarker for Ewing Sarcoma
Zhou, Y., Fang, Y., Zhou, J., Liu, Y., Wu, S., & Xu, B. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.771253 · Cited by 5
Molecular profile reveals immune-associated markers of medulloblastoma for different subtypes
Chen, J., Kang, Z., Li, S., Wang, C., Zheng, X., Cai, Z., Pan, L., Chen, F., & Li, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.911260 · Cited by 8
Proteostasis of immune checkpoint receptors
Tey, P. Y., Urbé, S., & Clague, M. J. (2025) · Biochemical Journal · doi:10.1042/bcj20253299 · Cited by 4
Singh, A., Vijver, S. V., Aglmous-Talibi, H., Jukic, N., Chen, P., Crawley, S., Mondal, K., Zhou, J., Niederauer, C., Matharu, Z., et al. (2025) · Science Signaling · doi:10.1126/scisignal.ado2768 · Cited by 4
Higashioka, K., Sowerby, J. M., Marks, K. E., Nunez, D. P., Bracero, S., Chang, M. H., Coblyn, J. S., Massarotti, E. M., Jones, B., Hao, L., et al. (2026) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2026.06.007 · Cited by 4
Differential ligand binding/trafficking for distinct CTLA-4 fates: is it an expandable mechanism?
Kim, J. E., Kim, E., & Lee, S. E. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00945-3 · Cited by 4
Immune profiling of premalignant lesions in patients with Peutz‐Jeghers syndrome
Liu, Z., Wu, B., Shi, X., Zhou, J., Huang, H., Li, Z., & Yang, M. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12650 · Cited by 4
Son, J., & Ha, S. (2019) · Immune Network · doi:10.4110/in.2019.19.e25 · Cited by 4
Papadimitriou, M., Liakouli, Z., & PAPADIMITRIOU, C. A. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.138 · Cited by 9
Song, Q., Nasri, U., Nakamura, R., Martin, P. J., & Zeng, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.907673 · Cited by 6
Walker, K., Waters, L. C., Kelly, G. P., Muskett, F. W., & Carr, M. D. (2022) · Biomolecular NMR Assignments · doi:10.1007/s12104-022-10092-5 · Cited by 4
Discovery of the first PD-1 ligand encoded by a pathogen
Martínez‐Vicente, P., Poblador, F., Leitner, J. M., Farré, D., Steinberger, P., Engel, P., & Angulo, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1007334 · Cited by 5
CTLA4 prohibits T cells from cross-dressing
Paillon, N., & Hivroz, C. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20230419 · Cited by 4
Sonnenburg, A., Stahlmann, R., Kreutz, R. H., & Peiser, M. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03506-3 · Cited by 4
Liu, G., Zhang, Z., Wu, Y., Feng, J., Lan, Y., Dong, D., Liu, Y., Yuan, H., Tai, G., Li, S., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110487 · Cited by 4
Cardiovascular Disease Risk Factors, Immune Checkpoints and Tregs
Shao, Y., Saaoud, F., Xu, K., Lu, Y., Jiang, X., Wang, H., & Yang, X. (2024) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-62806-1_2 · Cited by 4
Adaptive Immunity and the Tumor Microenvironment
., H., & Lotze (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_4 · Cited by 4
Hong, H., Shi, X., Ou, W., & Ou, P. (2024) · Biomedical Reports · doi:10.3892/br.2024.1751 · Cited by 3
On the same side: VISTA and its ligands interact in cis on the cell surface
Smorodinsky-Atias, K., Wiseglass, G., Artyukhova, A., Salem, M., Kashani, M., Boni, N., Lévy, R., & Rubinstein, R. (2025) · Protein Science · doi:10.1002/pro.70415 · Cited by 3
Fu, J., Lan, Y., Liang, Y., Yang, X., Tang, R., Wang, Y., Luo, Y., & Liu, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010407 · Cited by 3
Cui, X., Li, C., Zhong, X., Sun, A., Lan, Y., & Wang, Z. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189532 · Cited by 3
Opportunities and challenges for cancer immunotherapy based on antigen cross-presentation
Liu, P., Zhou, Z., Su, X., Xu, Y., & Li, J. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2635774 · Cited by 3
Liu, Y., Yang, F., Jin, Y., Zhang, Q., Zhao, B., Liang, Y., Hou, N., & Li, Q. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189601 · Cited by 4
The CTLA-4 Pathway in Human Disease: Molecular Mechanisms and Therapeutic Targeting
Negrini, S., Nicola, S., Badiu, I., Quinternetto, A., Vitali, I., Sardo, L. L., & Brussino, L. (2026) · Genes · doi:10.3390/genes17050574 · Cited by 3
VSTM2A reverses immunosuppression in colorectal cancer by antagonizing the PD-L1/PD-1 interaction
Dong, Y., Liu, J. J., Zhou, Y., Kang, W., Li, S., Cheung, A. H. K., Hu, Y., Liao, R. J., Wong, N., Wong, C. C., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.09.023 · Cited by 5
Emerging roles of checkpoint molecules on B cells
Asashima, H., Akao, S., & Matsumoto, I. (2025) · Immunological Medicine · doi:10.1080/25785826.2025.2454045 · Cited by 4
Masuda, C., Morinaga, M., Wakita, D., Yorozu, K., Kurasawa, M., Sugimoto, M., & Kondoh, O. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10135-6 · Cited by 3
Levy, D. A., Patel, J. J., Nguyen, S. A., Jungbauer, W. N., Neskey, D. M., Cohen, E. E. W., Paulos, C. M., Kaczmar, J. M., Knochelmann, H. M., & Day, T. A. (2022) · World Journal of Otorhinolaryngology - Head and Neck Surgery · doi:10.1002/wjo2.15 · Cited by 3
Metadata
- Authors
- Sugiura, D., Maruhashi, T., Okazaki, I.-M., Shimizu, K., Maeda, T. K., Takemoto, T., & Okazaki, T.
- Affiliations
- Institute of Advanced Medical Sciences, Tokushima University (JP)
- Corresponding author
- Sugiura, Daisuke
- Maruhashi, Takumi
- Okazaki, Il-mi
- Shimizu, Kenji
- Maeda, Takeo K.
- Okazaki, Taku
- ORCID
- Venue
- Science
- Published
- 2019-05-10
- Volume
- 364
- Issue
- 6440
- Pages
- 558-566
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2936616584
- Cited by
- 386
- References
- 40
- Citations by year
- 2026: 44 · 2025: 40 · 2024: 61 · 2023: 49 · 2022: 52 · 2021: 63 · 2020: 53 · 2019: 23
- FWCI
- 19.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Agency for Medical Research and Development (JP18am0301007)
- Japan Society for the Promotion of Science (JP18H05417)
- Core Research for Evolutional Science and Technology, Japan Science and Technology Agency
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, PD-L1, CD80, T cell activation, T cell suppression, costimulation, dendritic cells, anti-PD-1 therapy, PD-L1 blockade, cancer immunotherapy, immune checkpoint regulation
- MeSH terms
- Animals, Dendritic Cells, Humans, Immunotherapy, Lymphocyte Activation, Mice, Mutant Strains, Neoplasms, Protein Binding, T-Lymphocytes, Autoimmunity, CD28 Antigens, B7-1 Antigen, Mice, Gene Knock-In Techniques, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.